XTalks

MAY 23, 2024

Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays. In fact, tools such as dermatoscopes, digital imaging systems and artificial intelligence (AI)-powered diagnostic tools have become integral to dermatological practice.

Life Science 72

Life Science Dermatology Drug Delivery Systems Medicine 72

XTalks

JANUARY 2, 2024

The clinical study also highlighted the favorable tolerability profile of Filsuvez. The most commonly reported adverse reactions in the clinical trial were pruritus (itching) and pain at the wound application site, occurring in 7.3 Specifically, 41.3 percent observed in the control gel arm. percent of cases.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

Drug Discovery World

DECEMBER 16, 2022

An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials. . Experimental immunotherapy has over 70% response rate . New dermatitis treatment shows promising long-term results .

Drugs 52

Drugs Vaccination Vaccine Genetics 52

The Pharma Data

JANUARY 24, 2021

With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Read on to see. COVID-19-Related.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

JULY 23, 2021

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

MARCH 11, 2021

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

AUGUST 11, 2020

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52